Novo Nordisk announces innovation plans in rare blood disorders’ treatment
Novo Nordisk will be sharing its new data in the treatment of rare diseases which will be revealed at the International So…
Novo Nordisk will be sharing its new data in the treatment of rare diseases which will be revealed at the International So…
YOU ARE PHARMAVIEWS.NET US biomedical giant Moderna has announced plans to build a £1bn state-of-the-art research and m…
Hyderabad-based conglomerate INCOR Group and Renovis Labs , have entered into a new JV ‘INCOR Renovis’. The new company wi…
Drug-maker Aurobindo Pharma on June 27 informed the stock exchanges that it has received a "warning letter" …
In the pharmaceutical industry, AstraZeneca Pharma India Ltd. is a mid-cap company with a market cap of Rs. 6,822 crore. W…
Strides Pharma announced on June 24 results from a Phase II/III clinical trial in India of the SARS-CoV-2 vaccine, AKS-452,…
WASHINGTON, June 23(Reuters) - The Biden administration announced on Wednesday it is expanding monkeypox testing capacity …
Earlier this month, Beta Bionics presented clinical trial data to the American Diabetes Association (ADA) on its insulin-o…
New Delhi: In what is going to bring a major setback to the traditional pharma marketing of providing free physician'…
With the increased focus on digital transformation, pharma companies in India are prioritising data security, finds a Delo…
The U.S. FDA has issued Form 483 with six observations after an inspection at Glenmark Pharmaceuticals Limited's formu…
There has been recent reports in newspapers quoting IQVIA data about the de-growth in pharma market. Alembic Pharmaceutica…
Ahmedabad: Ethiopian Ambassador and Director General FDA inaugurated Cadila Pharma ’s new formulation development lab…
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announced today that it has signed defin…
The Company has received Form 483 with three observations. Alkem Laboratories Ltd has informed to the exchanges that US FD…
Our website uses cookies to improve your experience. Learn more
Ok